Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca Plc stock logo
AZN
AstraZeneca
$184.87
+0.2%
$168.82
$153.41
▼
$212.71
$286.80B0.242.82 million shs814,485 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$284.47
-0.4%
$266.97
$195.90
▼
$290.25
$684.87B0.227.92 million shs2.04 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$146.47
-0.9%
$146.16
$92.11
▼
$156.92
$361.59B0.1310.51 million shs1.77 million shs
Novartis AG stock logo
NVS
Novartis
$161.52
+0.6%
$149.13
$123.24
▼
$170.46
$308.36B0.42.00 million shs720,529 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca Plc stock logo
AZN
AstraZeneca
0.00%-1.05%+11.76%+17.67%+3.63%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.49%+11.83%+8.90%+45.80%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+0.57%+1.19%+8.56%+58.87%
Novartis AG stock logo
NVS
Novartis
0.00%-1.32%+6.62%+5.52%+22.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AstraZeneca Plc stock logo
AZN
AstraZeneca
$184.87
+0.2%
$168.82
$153.41
▼
$212.71
$286.80B0.242.82 million shs814,485 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$284.47
-0.4%
$266.97
$195.90
▼
$290.25
$684.87B0.227.92 million shs2.04 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$146.47
-0.9%
$146.16
$92.11
▼
$156.92
$361.59B0.1310.51 million shs1.77 million shs
Novartis AG stock logo
NVS
Novartis
$161.52
+0.6%
$149.13
$123.24
▼
$170.46
$308.36B0.42.00 million shs720,529 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AstraZeneca Plc stock logo
AZN
AstraZeneca
0.00%-1.05%+11.76%+17.67%+3.63%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+3.49%+11.83%+8.90%+45.80%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.00%+0.57%+1.19%+8.56%+58.87%
Novartis AG stock logo
NVS
Novartis
0.00%-1.32%+6.62%+5.52%+22.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AstraZeneca Plc stock logo
AZN
AstraZeneca
2.84
Moderate Buy$206.6710.98% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.92-3.70% Downside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$155.745.27% Upside
Novartis AG stock logo
NVS
Novartis
2.17
Hold$152.25-6.07% Downside

Current Analyst Ratings Breakdown

Latest NVS, JNJ, MRK, and AZN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Novartis AG stock logo
NVS
Novartis
DowngradeBuy (B) ➝ Buy (B-)
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeBuy ➝ Hold$153.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetHold$125.00 ➝ $140.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetNeutral$145.00 ➝ $155.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetOverweight$165.00 ➝ $175.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetSector Perform$145.00 ➝ $140.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Boost Price TargetBuy$170.00 ➝ $171.00
10/30/2026
Novartis AG stock logo
NVS
Novartis
DowngradeHold ➝ Sell
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingSector Perform
10/28/2026
Novartis AG stock logo
NVS
Novartis
Reiterated RatingNeutral
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AstraZeneca Plc stock logo
AZN
AstraZeneca
$62.38B4.63$13.05 per share14.27$31.41 per share5.93
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$99.34B6.94$14.16 per share20.24$33.85 per share8.46
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.61$11.43 per share12.94$21.22 per share6.97
Novartis AG stock logo
NVS
Novartis
$54.53B5.67$10.85 per share14.94$22.04 per share7.35
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AstraZeneca Plc stock logo
AZN
AstraZeneca
$10.23B$7.0726.3416.421.4317.68%31.85%13.62%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6043.4924.792.8216.20%31.64%13.04%1/26/2027 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.97152.6416.296.773.64%16.73%5.88%2/2/2027 (Estimated)
Novartis AG stock logo
NVS
Novartis
$13.98B$5.2430.9316.232.9418.11%41.04%14.45%2/3/2027 (Estimated)

Latest NVS, JNJ, MRK, and AZN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/31/2026Q3 2026
AstraZeneca Plc stock logo
AZN
AstraZeneca
$2.60$2.79+$0.19$2.00$16.00 billion$16.21 billion
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
10/27/2026Q3 2026
Novartis AG stock logo
NVS
Novartis
$2.25$2.46+$0.21$0.63$14.53 billion$15.03 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AstraZeneca Plc stock logo
AZN
AstraZeneca
$2.171.17%+2.30%30.69%N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.87%+5.25%81.21%64 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.30%+5.75%350.52%14 Years
Novartis AG stock logo
NVS
Novartis
$3.081.90%+5.28%58.78%N/A

Latest NVS, JNJ, MRK, and AZN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AstraZeneca Plc stock logo
AZN
AstraZeneca
0.51
1.01
0.79
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14
Novartis AG stock logo
NVS
Novartis
0.98
0.88
0.70

Institutional Ownership

CompanyInstitutional Ownership
AstraZeneca Plc stock logo
AZN
AstraZeneca
20.35%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%

Insider Ownership

CompanyInsider Ownership
AstraZeneca Plc stock logo
AZN
AstraZeneca
N/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Novartis AG stock logo
NVS
Novartis
0.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
AstraZeneca Plc stock logo
AZN
AstraZeneca
96,1001.55 billionN/AOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable
Novartis AG stock logo
NVS
Novartis
75,2671.91 billion1.91 billionOptionable

Recent News About These Companies

Novartis Stock Gets Weaker EPS Estimate from Zacks Research
Novartis (NVS) Stock Forecast & Price Target
Novartis FY2026 Earnings Forecast Boosted by Zacks Research
Ethic Inc. Acquires 17,059 Shares of Novartis AG $NVS
Novartis AG $NVS Shares Sold by MGO One Seven LLC

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AstraZeneca stock logo

AstraZeneca NYSE:AZN

$184.87 +0.42 (+0.23%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$284.46 -1.29 (-0.45%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$146.47 -1.29 (-0.87%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis stock logo

Novartis NYSE:NVS

$161.52 +1.02 (+0.64%)
As of 12:13 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.